Long-Term Inhibition of the Glucagon Receptor with a Monoclonal Antibody in Mice Causes Sustained Improvement in Glycemic Control, with Reversible α-Cell Hyperplasia and Hyperglucagonemia

Uncontrolled hepatic glucose output (HGO) contributes significantly to the pathological hyperglycemic state of patients with type 2 diabetes. Glucagon, through action on its receptor, stimulates HGO, thereby leading to increased glycemia. Antagonizing the glucagon signaling pathway represents an att...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of pharmacology and experimental therapeutics 2009-12, Vol.331 (3), p.871-881
Hauptverfasser:	Gu, Wei, Yan, Hai, Winters, Katherine A., Komorowski, Renée, Vonderfecht, Steven, Atangan, Larissa, Sivits, Glenn, Hill, David, Yang, Jie, Bi, Vivian, Shen, Yuqing, Hu, Sylvia, Boone, Tom, Lindberg, Richard A., Véniant, Murielle M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Blood Glucose Diabetes Mellitus, Experimental - blood Diabetes Mellitus, Experimental - drug therapy Diabetes Mellitus, Experimental - metabolism Glucagon - blood Glucagon-Secreting Cells - pathology Glucose - metabolism Hyperglycemia - blood Hyperglycemia - drug therapy Hyperglycemia - metabolism Hyperplasia Hypoglycemia - blood Hypoglycemia - metabolism Hypoglycemia - prevention & control Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Insulin - administration & dosage Insulin - therapeutic use Male Mice Mice, Inbred C57BL Obesity - blood Obesity - metabolism Receptors, Glucagon - antagonists & inhibitors Tachyphylaxis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!